Clin2
NCT06467968Possibly a fitRecruiting

Heart analysis during DOTATOC PET/CT for neuroendocrine tumors

Cardiac Inflammation

Part of Heart & circulation clinical trials.

This study looks at how a PET/CT scan (called gallium-68 DOTATOC) can also check your heart health while scanning for a neuroendocrine tumor. It aims to see if the routine scan can give extra information about your heart function without any extra visits or radiation.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
99 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your doctor has ordered a special type of PET/CT scan (called gallium-68 DOTATOC) to check for a neuroendocrine tumor.
  • You do not have a history of heart disease or a severe irregular heartbeat.
  • You are not currently taking a somatostatin analog (a medicine that can affect the scan).
  • You do not have severe kidney disease, Cushing's syndrome, or a known allergy to the scan tracer.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06455358Recruiting· Phase 1/Phase 2
A new PET scan to find neuroendocrine tumors

This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.

Basel, Canton of Basel-City
NCT05499637Recruiting· Phase 2
PET/CT scan using a special tracer for heart inflammation

This Phase 2 study tests whether a PET/CT scan using a radioactive tracer can help evaluate acute heart inflammation. It may help doctors better identify inflammation and guide follow-up, especially in people suspected of specific heart inflammation conditions or recently after heart transplant follow-up.

Lausanne, Canton of Vaud
NCT04847505Recruiting· Phase 3
Testing 68Ga-DOTA-TATE PET/CT scans for neuroendocrine tumors

This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.

Montreal, Quebec
NCT05673031Recruiting
PET/CT scan test for neuroendocrine tumors with a special tracer

This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.

Calgary, Alberta
NCT06611891Recruiting· Phase 3
PET scan study for breast cancer with hormone receptors

This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.

Grenoble
NCT06155318Recruiting
PET scan for neuroendocrine tumors

This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.

Milan

Hear when a new Cardiac Inflammation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.